Cesar Augusto R.
- Country
- France
- Department
- Oncology
Research Overview
- Evaluation of Neoadjuvant and Adjuvant Ribociclib and Letrozole in High-Risk Estrogen Receptor-Positive, HER2-Negative Breast Cancer
- Phase III Study on Palbociclib with Anti-HER2 and Endocrine Therapy in HR+/HER2+ Metastatic Breast Cancer Post-Induction Treatment
- Phase III Multicenter Open-Label Study Comparing Ribociclib and Palbociclib in Advanced Hormone Receptor-Positive/HER2-Negative/HER2-Enriched Breast Cancer
Data & Insights
Has run more than one trial at 35 of 101 partner sites.
Specializations
Hormone‑Responsive and Triple‑Negative Breast Cancer
Clinical investigation of endocrine‑resistant and high‑risk breast malignancies.
- Estrogen receptor‑positive HER2‑negative advanced disease
- Hormone‑receptor‑positive disease after CDK4/6 inhibitor failure
- Triple‑negative breast cancer with residual disease
- HER2‑low breast cancer with brain metastases
Trials integrate genomic profiling to guide combination regimens across Spanish oncology centers.
Non‑Small Cell and Small Cell Lung Cancer
Targeted and immunotherapeutic strategies for thoracic malignancies.
- KRAS‑G12C mutant NSCLC
- EGFR exon 20 insertion NSCLC
- MET‑amplified non‑squamous NSCLC
- Extensive‑stage small‑cell lung cancer
Multi‑institutional enrollment supports biomarker‑driven arms.
Hematologic Malignancies and Myelodysplastic Syndromes
Evaluation of novel agents in acute and chronic blood cancers.
- Acute myeloid leukemia with IDH1 mutation
- High‑risk myelodysplastic syndrome
- Diffuse large B‑cell lymphoma relapsed after standard therapy
- Chronic lymphocytic leukemia with TP53 alteration
Coordinated at university hospitals and specialized hematology centers.
Molecularly Targeted Solid Tumors
Therapies directed at actionable genomic alterations beyond common indications.
- MTAP‑deleted solid tumors
- IDH‑mutant glioma and cholangiocarcinoma
- FGFR2b‑positive gastric and biliary cancers
- HER2‑mutated non‑small cell lung cancer
Basket‑type protocols enable cross‑tumor evaluation of pathway inhibitors.
Immunotherapy for Rare and Aggressive Cancers
Checkpoint blockade and cellular therapies for underserved malignancies.
- Mesothelioma with PD‑L1 expression
- Neuroendocrine tumors expressing DLL3
- Advanced urothelial carcinoma refractory to chemotherapy
- Rare sarcomas including chordoma and Ewing sarcoma
Collaboration with European research networks expands access to innovative agents.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.